blank
logo-
Call: +66 64 505 5599

MENU

Call: +66 64 505 5599
logo-
Call: +66 64 505 5599
uc-msc-expansion-passage-cellular-aging

What the Science Actually Shows About Stem Cells Expansion

Passage Number, and Cellular Aging (2026 Evidence Review)

Why patients hear “passage number” and get confused

Umbilical cord–derived mesenchymal stem cells (UC-MSCs)are widely discussed in regenerative medicine, but the laboratory terms used to describe them are often oversimplified. “Passage number” is one of the most common examples. Patients may be told that a lower passage is always better, or that a specific passage such as P3 is superior to P4. The scientific literature does not support a universal “magic passage.” What it supports is more practical and more nuanced: UC-MSCs, like other MSCs, change gradually as they are expanded in culture, and the best predictor of cellular aging is usually the cumulative replication history, not the passage label alone.

What UC-MSCs are and why expansion is unavoidable

UC-MSCs are mesenchymal stromal cells isolated from umbilical cord tissue (often Wharton’s jelly). Because therapeutic dosing requires far more cells than can be isolated in one step, laboratories expand the cells in vitro under controlled conditions. Expansion means repeated cell divisions, and repeated divisions inevitably introduce biological drift over time. This is not unique to stem cells; it is a general feature of mammalian cell culture. The question for clinical translation is how to expand cells while maintaining identity, minimizing senescence burden, and ensuring consistent release quality.

What “passage number” actually measures (and what it does not)

A “passage” is a subculture event: cells are detached and re-seeded into a new vessel to continue growing. Passage number is therefore a handling counter. It does not directly measure how many times the cells have divided. Two laboratories can both report “P4,” yet one may have used different split ratios, seeding densities, or growth durations that produce very different total numbers of cell divisions. For this reason, cell culture authorities emphasize population doubling level (PDL) or cumulative population doublings (CPD) as a more biologically meaningful description of replicative age than passage number alone. PDL describes how many doublings the population has undergone, which correlates more closely with senescence signatures as culture continues.  

What the science shows across long-term MSC culture: a consistent pattern

Across long-term MSC expansion studies, the pattern is strikingly consistent even though the exact cutoffs vary by donor, tissue source, and manufacturing method. Early cultures tend to be fast-growing but heterogeneous. Early-to-mid expansion tends to be the most stable window for identity and function. Later expansion shows increasing evidence of replicative senescence, including slower proliferation and molecular aging markers. A classic study by Wagner and colleagues demonstrated that MSC replicative senescence is not a sudden event; it is a continuous and organized process that begins early and becomes progressively more evident with cumulative expansion. The key practical implication is that quality cannot be inferred from a single passage number without context.

What “early passage” really means in practice

Early passages (often labeled around P0–P2) are commonly characterized by rapid proliferation and higher heterogeneity. This is not necessarily a problem, but it is a biological reality: early cultures contain a mixture of subpopulations that may shift as cells adapt to culture conditions. Early cultures can therefore show more variability across donors and lots, even when basic identity markers remain positive. The best interpretation of early passage is not “best” or “worst,” but “more dynamic.” In quality systems, early culture behavior is one reason laboratories rely on standardized isolation and expansion protocols rather than assuming that being “very early” automatically ensures better clinical signaling.

What “early–mid passage” stability means and why many programs target it

In many clinical-grade workflows, early–mid passage (commonly within a range such as P2–P5, depending on the system) is targeted because identity and functional behavior often remain relatively stable compared with later expansion. This does not mean the cells are unchanged; it means that overt senescence signals are typically not dominant yet, and manufacturing is more likely to remain consistent lot-to-lot. Clinical translation also depends on what UC-MSCs are expected to do in the body. UC-MSCs are generally understood to act primarily through paracrine signaling and immunomodulation—release of cytokines, growth factors, and other mediators that influence inflammation and tissue repair signaling—rather than permanent engraftment into cartilage, meniscus, or neural tissue. Reviews of MSC immunomodulation describe these effects as context-dependent and influenced by the inflammatory environment

Cellular aging and late passage: what changes are consistently reported

With extended culture, MSCs increasingly show features associated with replicative senescence. These features include reduced proliferation (longer doubling times), altered morphology (enlarged, flattened cells), and shifts in senescence-associated pathways. Epigenetic drift has also been documented during replicative aging, including DNA methylation changes that correlate with senescence progression. Importantly, these changes track better with cumulative replication history than with the passage label alone. Schellenberg and colleagues provided evidence of senescence-associated DNA methylation changes during MSC expansion, reinforcing that “cell age” is an accumulating process rather than a single passage threshold.

Why PDL matters more than passage number for real-world interpretation

Because passage number is a proxy, it can mislead if used as a standalone quality claim. PDL is more informative because it captures cumulative replication burden, which is closer to the biology of senescence. A “P4” product could be relatively young in one lab and relatively aged in another if the cumulative doublings differ. This is why high-quality manufacturing typically monitors not only passage but also growth kinetics, viability, identity, sterility, and other release criteria. For medically literate patients, the more meaningful question is not “What passage?” but “How do you track replication burden and confirm the product is within a controlled expansion window?”

How UC-MSCs behave after administration: paracrine signaling, immunomodulation, and homing

UC-MSCs do not typically persist long-term as living, engrafted cells after systemic administration. Experimental and translational data show that intravenously infused MSCs are largely trapped in the lungs initially (the pulmonary first-pass effect), and viable cells may be short-lived. This does not mean there is no biological effect; rather, it supports the concept that effects are time-dependent and mediated through signaling mechanisms rather than permanent cell replacement. Reviews on MSC homing and studies on post-infusion distribution help explain why “homing” is often limited and why clinical effects—when observed—should be framed as biological modulation, not guaranteed tissue rebuilding. 

What clinical evidence suggests for UC-MSCs and why it does not settle the passage debate

Clinical trials in specific indications help inform safety and feasibility, but they are not designed to compare manufacturing variables such as whether P3 is superior to P4. Published studies typically report outcomes using defined expansion windows without isolating passage number as an independent predictor of efficacy. Therefore, current clinical evidence does not support the claim that one specific early–mid passage is universally superior. Quality depends more on controlled expansion, replication burden, and release criteria than on passage labeling alone.

Safety considerations: what is known, what remains uncertain

From a clinical safety standpoint, the strongest recurring message in the literature is that MSC therapy appears to have an overall favorable short-term safety profile in controlled trials, while long-term and indication-specific uncertainties remain. A widely cited systematic review and meta-analysis found no clear signal for many serious adverse events compared with controls, but it did find an association with transient fever, and it emphasized the need for larger trials and rigorous adverse-event reporting. In real-world practice, the most preventable serious harms tend to be related to product quality failures (such as contamination) or inappropriate clinical use, rather than to the concept of MSCs itself. 

Realistic expectation framing: what patients should take away

Patients should interpret UC-MSC therapy as a regenerative medicine strategy aimed at biological modulation—primarily inflammation and repair signaling—rather than a permanent implant. The cells do not permanently remain, and outcomes are time-dependent and variable. Passage number can be one useful descriptor of manufacturing stage, but it should never be the only one. The most scientifically grounded way to evaluate quality is to ask how the laboratory tracks replication burden (PDL), how it screens for contamination, how it confirms identity and viability, and what follow-up framework exists to measure response over time.

FAQ:

  • Is P3 always better than P4 for UC-MSCs?
    No. The literature does not support a universal ranking of P3 over P4. Replicative age correlates more strongly with cumulative population doublings and overall culture conditions than with the passage label alone
  • Do UC-MSCs permanently stay in the body after infusion? 
    Current evidence suggests viable MSCs are often short-lived after intravenous infusion and are initially trapped in the lungs. Clinical effects, when present, are generally explained by paracrine and immunomodulatory signaling rather than permanent engraftment
  • Does late passage automatically mean unsafe? 
    Not automatically, but later expansion is associated with stronger senescence signatures and slower growth in many studies. This is why manufacturing programs aim to control expansion and monitor quality indicators rather than expand indefinitely.
About EDNA Wellness

EDNA Wellness is a private Stem Cell Clinic and Regenerative Medicine Center in Bangkok, Thailand, specializing in Umbilical cord–derived Mesenchymal Stem Cells (UC-MSCs) for knee osteoarthritis and joint pain, stroke and other neuro-related conditions, and stem cell IV infusions for longevity and healthy aging. All treatments are doctor-designed and performed in a sterile clinical setting.

For more information or to book a consultation:

LINE: @ednawellness

WhatsApp: +66 (0) 64 505 5599

Website: www.ednawellness.com

References

Related Posts

error:Content is protected !!
blank